Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C7H8O2 |
| Molecular Weight | 124.1372 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(O)C=C1
InChI
InChIKey=NWVVVBRKAWDGAB-UHFFFAOYSA-N
InChI=1S/C7H8O2/c1-9-7-4-2-6(8)3-5-7/h2-5,8H,1H3
Mequinol (mequinol is 4-hydroxyanisole) is an active ingredient in topical drugs used for skin depigmentation. The mechanism of action of mequinol is unknown. Although mequinol is a substrate for the enzyme tyrosinase and acts as a competitive inhibitor of the formation of melanin precursors, the clinical significance of these findings is unknown.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1973 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | SOLAGE Approved UseMequinol is a depigmenting agent. The mechanism of depigmenting effects of mequinol remain unclear; speculations include oxidation by tyrosinase to cytotoxic products in melanocytes, a direct/selective toxic effect on melanocytes, or inhibition of melanin formation Launch Date1999 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
9.92 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10701701/ |
16 μL 1 times / day steady-state, topical dose: 16 μL route of administration: Topical experiment type: STEADY-STATE co-administered: |
MEQUINOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
33.43 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10701701/ |
16 μL 1 times / day steady-state, topical dose: 16 μL route of administration: Topical experiment type: STEADY-STATE co-administered: |
MEQUINOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10701701/ |
16 μL 1 times / day steady-state, topical dose: 16 μL route of administration: Topical experiment type: STEADY-STATE co-administered: |
MEQUINOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
2 % 1 times / day steady, topical Recommended Dose: 2 %, 1 times / day Route: topical Route: steady Dose: 2 %, 1 times / day Sources: |
healthy, 55.8 years Health Status: healthy Age Group: 55.8 years Sex: M+F Sources: |
Disc. AE: Dermal and epidermal conditions NEC, Skin and subcutaneous tissue disorders... Other AEs: Hematuria... AEs leading to discontinuation/dose reduction: Dermal and epidermal conditions NEC (3.5%) Other AEs:Skin and subcutaneous tissue disorders (5.8%) Hematuria (3.5%) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Hematuria | 3.5% | 2 % 1 times / day steady, topical Recommended Dose: 2 %, 1 times / day Route: topical Route: steady Dose: 2 %, 1 times / day Sources: |
healthy, 55.8 years Health Status: healthy Age Group: 55.8 years Sex: M+F Sources: |
| Dermal and epidermal conditions NEC | 3.5% Disc. AE |
2 % 1 times / day steady, topical Recommended Dose: 2 %, 1 times / day Route: topical Route: steady Dose: 2 %, 1 times / day Sources: |
healthy, 55.8 years Health Status: healthy Age Group: 55.8 years Sex: M+F Sources: |
| Skin and subcutaneous tissue disorders | 5.8% Disc. AE |
2 % 1 times / day steady, topical Recommended Dose: 2 %, 1 times / day Route: topical Route: steady Dose: 2 %, 1 times / day Sources: |
healthy, 55.8 years Health Status: healthy Age Group: 55.8 years Sex: M+F Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The influence of fibrous elastomer structure and porosity on matrix organization. | 2010-12-22 |
|
| Pairwise substitution effects, inter- and intramolecular hydrogen bonds in methoxyphenols and dimethoxybenzenes. Thermochemistry, calorimetry, and first-principles calculations. | 2010-12-16 |
|
| Rate coefficients for the gas-phase reaction of hydroxyl radicals with 2-methoxyphenol (guaiacol) and related compounds. | 2010-11-04 |
|
| Structure and vibrational frequencies of 6,7-dimethoxy-1,4-dihydro-1,3-quinoxalinedione based on density functional theory calculations: The role of pi-electron conjugation and back-donation. | 2010-09-15 |
|
| Molecular characteristics of Kraft-AQ pulping lignin fractionated by sequential organic solvent extraction. | 2010-08-16 |
|
| Pi-selective stationary phases: (II) Adsorption behaviour of substituted aromatic compounds on n-alkyl-phenyl stationary phases. | 2010-08-13 |
|
| Synthesis and characterization of amine bridged bis(phenolate) lanthanide aryloxides and their application in the polymerization of lactide. | 2010-08-07 |
|
| Hydrogen hyperfine splitting constants for phenoxyl radicals by DFT methods: regression analysis unravels hydrogen bonding effects. | 2010-07-21 |
|
| Surface photochemistry of pesticides containing 4-chlorophenoxyl chromophore. | 2010-07-15 |
|
| Application of ex situ dynamic nuclear polarization in studying small molecules. | 2010-06-14 |
|
| Heterogeneous reaction of gaseous ozone with aqueous iodide in the presence of aqueous organic species. | 2010-05-20 |
|
| In vivo anti-inflammatory action of eugenol on lipopolysaccharide-induced lung injury. | 2010-04 |
|
| Depigmentation therapy in vitiligo universalis with cryotherapy and 4-hydroxyanisole. | 2010-03 |
|
| Strategic distribution of protective proteins within bran layers of wheat protects the nutrient-rich endosperm. | 2010-03 |
|
| Amperometric phenol biosensor based on horseradish peroxidase entrapped PVF and PPy composite film coated GC electrode. | 2010-03 |
|
| Radical-scavenging activity and cytotoxicity of p-methoxyphenol and p-cresol dimers. | 2010-02-26 |
|
| Marine natural meroterpenes: synthesis and antiproliferative activity. | 2010-02-23 |
|
| Structure-toxicity relationship of phenolic analogs as anti-melanoma agents: an enzyme directed prodrug approach. | 2010-02-12 |
|
| Measurement of phenols dearomatization via electrolysis: the UV-Vis solid phase extraction method. | 2010-02 |
|
| Antioxidant activity of colored rice bran obtained at different milling yields. | 2010 |
|
| The hunt for natural skin whitening agents. | 2009-12-10 |
|
| Tris{2-meth-oxy-6-[(4-methyl-phen-yl)iminiometh-yl]phenolate-κO,O'}tris-(thio-cyanato-κN)europium(III). | 2009-11-21 |
|
| (E)-2-[(4-Ethoxy-phen-yl)imino-meth-yl]-4-methoxy-phenol. | 2009-10-10 |
|
| Development and evaluation of kinetic spectrophotometric assays for horseradish peroxidase by catalytic coupling of paraphenylenediamine and mequinol. | 2009-10 |
|
| 6,6'-Dimeth-oxy-2,2'-[(E,E')-(4-chloro-m-phenyl-ene)bis-(nitrilo-methyl-idyne)]diphenol. | 2009-09-30 |
|
| Mechanisms regulating skin pigmentation: the rise and fall of complexion coloration. | 2009-09-15 |
|
| Simulation of IR and Raman spectra of p-hydroxyanisole and p-nitroanisole based on scaled DFT force fields and their vibrational assignments. | 2009-09-15 |
|
| Increase in the levels of chaperone proteins by exposure to beta-estradiol, bisphenol A and 4-methoxyphenol in human cells transfected with estrogen receptor alpha cDNA. | 2009-06 |
|
| Current and emerging therapy for the management of vitiligo. | 2009-03-12 |
|
| Peroxidase-mediated degradation of perfluorooctanoic acid. | 2009-02 |
|
| Production of o-diphenols by immobilized mushroom tyrosinase. | 2009-01-15 |
|
| Urinary levoglucosan as a biomarker of wood smoke exposure: observations in a mouse model and in children. | 2009-01 |
|
| Topical treatment of melasma. | 2009 |
|
| Antiproliferative effects of honey and of its polyphenols: a review. | 2009 |
|
| Reaction of phenols with the 2,2-diphenyl-1-picrylhydrazyl radical. Kinetics and DFT calculations applied to determine ArO-H bond dissociation enthalpies and reaction mechanism. | 2008-12-05 |
|
| Results of a residential indoor PM2.5 sampling program before and after a woodstove changeout. | 2008-10 |
|
| The mechanism of the phosphoramidite synthesis of polynucleotides. | 2008-09-21 |
|
| Analytic quantification of the bleaching effect of a 4-hydroxyanisole-tretinoin combination on actinic lentigines. | 2008-09 |
|
| Assessing urinary levoglucosan and methoxyphenols as biomarkers for use in woodsmoke exposure studies. | 2008-08-25 |
|
| Essential explanation of the strong mineralization performance of boron-doped diamond electrodes. | 2008-07-01 |
|
| A highly specific BODIPY-based fluorescent probe for the detection of hypochlorous acid. | 2008-06-05 |
|
| An efficient protocol for the enantioselective preparation of a key polyfunctionalized cyclohexane. New access to (R)- and (S)-4-Hydroxy-2-cyclohexenone and (R)- and (S)-trans-cyclohex-2-ene-1,4-diol. | 2008-05-02 |
|
| Metabolic bioactivation and toxicity of ethyl 4-hydroxybenzoate in human SK-MEL-28 melanoma cells. | 2008-05 |
|
| Laser flash photolysis study of the triplet reactivity of beta-lapachones. | 2008-04 |
|
| Efficient synthesis and properties of novel near-infrared electrochromic anthraquinone imides. | 2008-02-21 |
|
| Mequinol 2%/tretinoin 0.01% topical solution for the treatment of melasma in men: a case series and review of the literature. | 2008-02 |
|
| Subcellular localization and cytoplasmic complex status of endogenous Keap1. | 2007-10 |
|
| Electrochemical oxidation characteristics of p-substituted phenols using a boron-doped diamond electrode. | 2007-09-15 |
|
| Suppression of interleukin-2 gene expression by isoeugenol is mediated through down-regulation of NF-AT and NF-kappaB. | 2007-09 |
|
| Physico-chemical studies on the evaluation of the antioxidant activity of herbal extracts and active principles of some Indian medicinal plants. | 2007-05 |
Patents
Sample Use Guides
Apply Solagé to the solar lentigines using the applicator tip while avoiding application to the surrounding skin. Use twice daily, morning and evening at least 8 hours apart, or as directed by a physician. Patients should not shower or bathe the treatment areas for at least 6 hours after application of Solagé. Special caution should be taken when applying Solagé to avoid the eyes, mouth, paranasal creases, and mucous membranes.
Route of Administration:
Topical
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C78284
Created by
admin on Mon Mar 31 17:34:41 GMT 2025 , Edited by admin on Mon Mar 31 17:34:41 GMT 2025
|
||
|
NDF-RT |
N0000175851
Created by
admin on Mon Mar 31 17:34:41 GMT 2025 , Edited by admin on Mon Mar 31 17:34:41 GMT 2025
|
||
|
WHO-ATC |
D11AX06
Created by
admin on Mon Mar 31 17:34:41 GMT 2025 , Edited by admin on Mon Mar 31 17:34:41 GMT 2025
|
||
|
NDF-RT |
N0000175855
Created by
admin on Mon Mar 31 17:34:41 GMT 2025 , Edited by admin on Mon Mar 31 17:34:41 GMT 2025
|
||
|
NDF-RT |
N0000175850
Created by
admin on Mon Mar 31 17:34:41 GMT 2025 , Edited by admin on Mon Mar 31 17:34:41 GMT 2025
|
||
|
CFR |
21 CFR 176.170
Created by
admin on Mon Mar 31 17:34:41 GMT 2025 , Edited by admin on Mon Mar 31 17:34:41 GMT 2025
|
||
|
WHO-VATC |
QD11AX06
Created by
admin on Mon Mar 31 17:34:41 GMT 2025 , Edited by admin on Mon Mar 31 17:34:41 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB09516
Created by
admin on Mon Mar 31 17:34:41 GMT 2025 , Edited by admin on Mon Mar 31 17:34:41 GMT 2025
|
PRIMARY | |||
|
150-76-5
Created by
admin on Mon Mar 31 17:34:41 GMT 2025 , Edited by admin on Mon Mar 31 17:34:41 GMT 2025
|
PRIMARY | |||
|
CHEMBL544
Created by
admin on Mon Mar 31 17:34:41 GMT 2025 , Edited by admin on Mon Mar 31 17:34:41 GMT 2025
|
PRIMARY | |||
|
4258
Created by
admin on Mon Mar 31 17:34:41 GMT 2025 , Edited by admin on Mon Mar 31 17:34:41 GMT 2025
|
PRIMARY | |||
|
15080
Created by
admin on Mon Mar 31 17:34:41 GMT 2025 , Edited by admin on Mon Mar 31 17:34:41 GMT 2025
|
PRIMARY | RxNorm | ||
|
6HT8U7K3AM
Created by
admin on Mon Mar 31 17:34:41 GMT 2025 , Edited by admin on Mon Mar 31 17:34:41 GMT 2025
|
PRIMARY | |||
|
1542
Created by
admin on Mon Mar 31 17:34:41 GMT 2025 , Edited by admin on Mon Mar 31 17:34:41 GMT 2025
|
PRIMARY | |||
|
6827
Created by
admin on Mon Mar 31 17:34:41 GMT 2025 , Edited by admin on Mon Mar 31 17:34:41 GMT 2025
|
PRIMARY | |||
|
205-769-8
Created by
admin on Mon Mar 31 17:34:41 GMT 2025 , Edited by admin on Mon Mar 31 17:34:41 GMT 2025
|
PRIMARY | |||
|
SUB08764MIG
Created by
admin on Mon Mar 31 17:34:41 GMT 2025 , Edited by admin on Mon Mar 31 17:34:41 GMT 2025
|
PRIMARY | |||
|
DTXSID4020828
Created by
admin on Mon Mar 31 17:34:41 GMT 2025 , Edited by admin on Mon Mar 31 17:34:41 GMT 2025
|
PRIMARY | |||
|
100000081706
Created by
admin on Mon Mar 31 17:34:41 GMT 2025 , Edited by admin on Mon Mar 31 17:34:41 GMT 2025
|
PRIMARY | |||
|
LL-42
Created by
admin on Mon Mar 31 17:34:41 GMT 2025 , Edited by admin on Mon Mar 31 17:34:41 GMT 2025
|
PRIMARY | |||
|
C47604
Created by
admin on Mon Mar 31 17:34:41 GMT 2025 , Edited by admin on Mon Mar 31 17:34:41 GMT 2025
|
PRIMARY | |||
|
4221
Created by
admin on Mon Mar 31 17:34:41 GMT 2025 , Edited by admin on Mon Mar 31 17:34:41 GMT 2025
|
PRIMARY | |||
|
C009760
Created by
admin on Mon Mar 31 17:34:41 GMT 2025 , Edited by admin on Mon Mar 31 17:34:41 GMT 2025
|
PRIMARY | |||
|
4960
Created by
admin on Mon Mar 31 17:34:41 GMT 2025 , Edited by admin on Mon Mar 31 17:34:41 GMT 2025
|
PRIMARY | |||
|
9015
Created by
admin on Mon Mar 31 17:34:41 GMT 2025 , Edited by admin on Mon Mar 31 17:34:41 GMT 2025
|
PRIMARY | |||
|
MEQUINOL
Created by
admin on Mon Mar 31 17:34:41 GMT 2025 , Edited by admin on Mon Mar 31 17:34:41 GMT 2025
|
PRIMARY |
ACTIVE MOIETY